Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Optimizing future lung transplant outcomes: asking the right questions for an alternative truth.

Vos R, Dobbels F, Van Raemdonck DE, Verleden GM.

Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466619897879. doi: 10.1177/1753466619897879. No abstract available.

2.

Small airways pathology in idiopathic pulmonary fibrosis: a retrospective cohort study.

Verleden SE, Tanabe N, McDonough JE, Vasilescu DM, Xu F, Wuyts WA, Piloni D, De Sadeleer L, Willems S, Mai C, Hostens J, Cooper JD, Verbeken EK, Verschakelen J, Galban CJ, Van Raemdonck DE, Colby TV, Decramer M, Verleden GM, Kaminski N, Hackett TL, Vanaudenaerde BM, Hogg JC.

Lancet Respir Med. 2020 Feb 13. pii: S2213-2600(19)30356-X. doi: 10.1016/S2213-2600(19)30356-X. [Epub ahead of print]

PMID:
32061334
3.

Histopathologic and radiologic assessment of nontransplanted donor lungs.

Vanstapel A, Dubbeldam A, Weynand B, Verbeken EK, Vos R, Neyrinck AP, Vasilescu DM, Ceulemans LJ, Frick AE, Van Raemdonck DE, Verschakelen J, Vanaudenaerde BM, Verleden GM, Verleden SE.

Am J Transplant. 2020 Jan 27. doi: 10.1111/ajt.15790. [Epub ahead of print]

PMID:
31985888
4.

Total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation: a single-center experience and review of literature.

Lebeer M, Kaes J, Lambrech M, Vanstapel A, Beeckmans H, Ambrocio GPL, Vanaudenaerde BM, Verleden SE, Verbeken EK, Neyrinck AP, Ceulemans LJ, Van Raemdonck DE, Verleden GM, Vos R; Leuven Lung Transplant Group.

Transpl Int. 2020 Feb;33(2):216-228. doi: 10.1111/tri.13544. Epub 2019 Nov 19.

PMID:
31643104
5.

Mortality after lung transplantation: a single-centre cohort analysis.

Raskin J, Vanstapel A, Verbeken EK, Beeckmans H, Vanaudenaerde BM, Verleden SE, Neyrinck AP, Ceulemans LJ, Van Raemdonck DE, Verleden GM, Vos R; Leuven Lung Transplant Group.

Transpl Int. 2020 Feb;33(2):130-141. doi: 10.1111/tri.13540. Epub 2019 Nov 18.

PMID:
31612514
6.

Intragraft donor-specific anti-HLA antibodies in phenotypes of chronic lung allograft dysfunction.

Sacreas A, Taupin JL, Emonds MP, Daniëls L, Van Raemdonck DE, Vos R, Verleden GM, Vanaudenaerde BM, Roux A, Verleden SE; and the Leuven Lung Transplant Group.

Eur Respir J. 2019 Nov 7;54(5). pii: 1900847. doi: 10.1183/13993003.00847-2019. Print 2019 Nov.

PMID:
31439680
7.

Myeloid-Derived Suppressor Cells in Lung Transplantation.

Heigl T, Singh A, Saez-Gimenez B, Kaes J, Van Herck A, Sacreas A, Beeckmans H, Vanstapel A, Verleden SE, Van Raemdonck DE, Verleden G, Vanaudenaerde BM, Hartl D, Vos R.

Front Immunol. 2019 Apr 26;10:900. doi: 10.3389/fimmu.2019.00900. eCollection 2019.

8.

Prone Positioning During Ex Vivo Lung Perfusion Influences Regional Edema Accumulation.

Ordies S, Frick AE, Claes S, Schols D, Verleden SE, Van Raemdonck DE, Neyrinck AP; Leuven Lung Transplant Group.

J Surg Res. 2019 Jul;239:300-308. doi: 10.1016/j.jss.2019.02.003. Epub 2019 Mar 19.

PMID:
30901722
9.

The pleural mesothelium and transforming growth factor-β1 pathways in restrictive allograft syndrome: A pre-clinical investigation.

Sacreas A, von der Thüsen JH, van den Bosch TPP, Weynand B, Verbeken EK, Debbaut C, Van Raemdonck DE, Vos R, Verleden SE.

J Heart Lung Transplant. 2019 May;38(5):570-579. doi: 10.1016/j.healun.2019.02.001. Epub 2019 Feb 6.

PMID:
30819647
10.

Montelukast in chronic lung allograft dysfunction after lung transplantation.

Vos R, Eynde RV, Ruttens D, Verleden SE, Vanaudenaerde BM, Dupont LJ, Yserbyt J, Verbeken EK, Neyrinck AP, Van Raemdonck DE, Verleden GM; Leuven Lung Transplant Group.

J Heart Lung Transplant. 2019 May;38(5):516-527. doi: 10.1016/j.healun.2018.11.014. Epub 2018 Dec 6.

PMID:
30638839
11.

Role of 18F-FDG PET/CT in Restrictive Allograft Syndrome After Lung Transplantation.

Verleden SE, Gheysens O, Goffin KE, Vanaudenaerde BM, Verbeken EK, Weynand B, Van Raemdonck DE, Verleden GM, Vos R.

Transplantation. 2019 Apr;103(4):823-831. doi: 10.1097/TP.0000000000002393.

PMID:
30086092
12.

Pirfenidone in restrictive allograft syndrome after lung transplantation: A case series.

Vos R, Wuyts WA, Gheysens O, Goffin KE, Schaevers V, Verleden SE, Van Herck A, Sacreas A, Heigl T, McDonough JE, Yserbyt J, Godinas L, Dupont LJ, Neyrinck AP, Van Raemdonck DE, Verbeken EK, Vanaudenaerde BM, Verleden GM.

Am J Transplant. 2018 Dec;18(12):3045-3059. doi: 10.1111/ajt.15019. Epub 2018 Aug 17.

13.

Montelukast for bronchiolitis obliterans syndrome after lung transplantation: A randomized controlled trial.

Ruttens D, Verleden SE, Demeyer H, Van Raemdonck DE, Yserbyt J, Dupont LJ, Vanaudenaerde BM, Vos R, Verleden GM.

PLoS One. 2018 Apr 6;13(4):e0193564. doi: 10.1371/journal.pone.0193564. eCollection 2018.

14.

Multiple Solid Organ Transplantation in Telomeropathy: Case Series and Literature Review.

Lebeer M, Wuyts WA, Cassiman D, Laleman W, Nevens F, Pirenne J, Monbaliu D, Roskams T, Verbeken EK, Neyrinck AP, Van Raemdonck DE, Verleden GM, Vos R.

Transplantation. 2018 Oct;102(10):1747-1755. doi: 10.1097/TP.0000000000002198. Review.

PMID:
29596117
15.

Immediate post-operative broncho-alveolar lavage IL-6 and IL-8 are associated with early outcomes after lung transplantation.

Verleden SE, Martens A, Ordies S, Neyrinck AP, Van Raemdonck DE, Verleden GM, Vanaudenaerde BM, Vos R.

Clin Transplant. 2018 Apr;32(4):e13219. doi: 10.1111/ctr.13219. Epub 2018 Feb 23.

PMID:
29405435
16.

Donor-specific and -nonspecific HLA antibodies and outcome post lung transplantation.

Verleden SE, Vanaudenaerde BM, Emonds MP, Van Raemdonck DE, Neyrinck AP, Verleden GM, Vos R.

Eur Respir J. 2017 Nov 16;50(5). pii: 1701248. doi: 10.1183/13993003.01248-2017. Print 2017 Nov.

17.

Solid Organ Transplantation in Sarcoidosis.

Yserbyt J, Wuyts WA, Verleden SE, Verleden GM, Van Raemdonck DE, Verbeken EK, Vanaudenaerde BM, Vos R.

Semin Respir Crit Care Med. 2017 Aug;38(4):538-545. doi: 10.1055/s-0037-1602383. Epub 2017 Jul 27. Review. No abstract available.

PMID:
28750467
18.

Immunoregulatory effects of multipotent adult progenitor cells in a porcine ex vivo lung perfusion model.

Martens A, Ordies S, Vanaudenaerde BM, Verleden SE, Vos R, Van Raemdonck DE, Verleden GM, Roobrouck VD, Claes S, Schols D, Verbeken E, Verfaillie CM, Neyrinck AP.

Stem Cell Res Ther. 2017 Jul 5;8(1):159. doi: 10.1186/s13287-017-0603-5.

19.

A retrospective database analysis to evaluate the potential of ex vivo lung perfusion to recruit declined lung donors.

Martens A, Van Raemdonck DE, Smits J, Verleden SE, Vos R, Vanaudenaerde BM, Verleden GM, Degezelle K, Desschans B, Neyrinck AP.

Transpl Int. 2017 Oct;30(10):1002-1010. doi: 10.1111/tri.12990. Epub 2017 Jul 13.

20.

A porcine ex vivo lung perfusion model with maximal argon exposure to attenuate ischemia-reperfusion injury.

Martens A, Ordies S, Vanaudenaerde BM, Verleden SE, Vos R, Verleden GM, Verbeken EK, Van Raemdonck DE, Claes S, Schols D, Chalopin M, Katz I, Farjot G, Neyrinck AP.

Med Gas Res. 2017 Mar 30;7(1):28-36. doi: 10.4103/2045-9912.202907. eCollection 2017 Jan-Mar.

21.

Post-transplant lymphoproliferative disease in lung transplantation: A nested case-control study.

Leyssens A, Dierickx D, Verbeken EK, Tousseyn T, Verleden SE, Vanaudenaerde BM, Dupont LJ, Yserbyt J, Verleden GM, Van Raemdonck DE, Vos R.

Clin Transplant. 2017 Jul;31(7). doi: 10.1111/ctr.12983. Epub 2017 May 8.

PMID:
28383790
22.

High-dose vitamin D after lung transplantation: A randomized trial.

Vos R, Ruttens D, Verleden SE, Vandermeulen E, Bellon H, Van Herck A, Sacreas A, Heigl T, Schaevers V, Van Raemdonck DE, Verbeken EK, Neyrinck AP, Dupont LJ, Yserbyt J, Vanaudenaerde BM, Verleden GM.

J Heart Lung Transplant. 2017 Aug;36(8):897-905. doi: 10.1016/j.healun.2017.03.008. Epub 2017 Mar 8.

PMID:
28365177
23.

Radiological Analysis of Unused Donor Lungs: A Tool to Improve Donor Acceptance for Transplantation?

Verleden SE, Martens A, Ordies S, Heigl T, Bellon H, Vandermeulen E, Van Herck A, Sacreas A, Verschakelen J, Coudyzer W, Van Raemdonck DE, Vos R, Weynand B, Verleden GM, Vanaudenaerde B, Neyrinck A.

Am J Transplant. 2017 Jul;17(7):1912-1921. doi: 10.1111/ajt.14255. Epub 2017 Mar 30.

24.

Immunological diversity in phenotypes of chronic lung allograft dysfunction: a comprehensive immunohistochemical analysis.

Vandermeulen E, Lammertyn E, Verleden SE, Ruttens D, Bellon H, Ricciardi M, Somers J, Bracke KR, Van Den Eynde K, Tousseyn T, Brusselle GG, Verbeken EK, Verschakelen J, Emonds MP, Van Raemdonck DE, Verleden GM, Vos R, Vanaudenaerde BM.

Transpl Int. 2017 Feb;30(2):134-143. doi: 10.1111/tri.12882. Epub 2016 Dec 8.

25.

Parametric Response Mapping of Bronchiolitis Obliterans Syndrome Progression After Lung Transplantation.

Verleden SE, Vos R, Vandermeulen E, Ruttens D, Bellon H, Heigl T, Van Raemdonck DE, Verleden GM, Lama V, Ross BD, Galbán CJ, Vanaudenaerde BM.

Am J Transplant. 2016 Nov;16(11):3262-3269. doi: 10.1111/ajt.13945. Epub 2016 Jul 29.

26.

The role of recipient derived interleukin-17A in a murine orthotopic lung transplant model of restrictive chronic lung allograft dysfunction.

Yamada Y, Vandermeulen E, Heigl T, Somers J, Vaneylen A, Verleden SE, Bellon H, De Vleeschauwer S, Verbeken EK, Van Raemdonck DE, Vos R, Verleden GM, Jungraithmayr W, Vanaudenaerde BM.

Transpl Immunol. 2016 Nov;39:10-17. doi: 10.1016/j.trim.2016.10.001. Epub 2016 Oct 11.

PMID:
27737799
27.

Thin-Section CT Features of Idiopathic Pulmonary Fibrosis Correlated with Micro-CT and Histologic Analysis.

Mai C, Verleden SE, McDonough JE, Willems S, De Wever W, Coolen J, Dubbeldam A, Van Raemdonck DE, Verbeken EK, Verleden GM, Hogg JC, Vanaudenaerde BM, Wuyts WA, Verschakelen JA.

Radiology. 2017 Apr;283(1):252-263. doi: 10.1148/radiol.2016152362. Epub 2016 Oct 6.

28.

First-in-man observation of Talaromyces marneffei-transmission by organ transplantation.

Hermans F, Ombelet S, Degezelle K, Testelmans D, Van Raemdonck DE, Verleden GM, Verbeken EK, Van Bleyenbergh P, Lagrou K, Vos R.

Mycoses. 2017 Mar;60(3):213-217. doi: 10.1111/myc.12574. Epub 2016 Sep 30.

PMID:
27687582
29.

Humoral immunity in phenotypes of chronic lung allograft dysfunction: A broncho-alveolar lavage fluid analysis.

Vandermeulen E, Verleden SE, Bellon H, Ruttens D, Lammertyn E, Claes S, Vandooren J, Ugarte-Berzal E, Schols D, Emonds MP, Van Raemdonck DE, Opdenakker G, Verleden GM, Vos R, Vanaudenaerde BM.

Transpl Immunol. 2016 Sep;38:27-32. doi: 10.1016/j.trim.2016.08.004. Epub 2016 Aug 22.

PMID:
27561239
30.

Predictors of survival in restrictive chronic lung allograft dysfunction after lung transplantation.

Verleden SE, Ruttens D, Vandermeulen E, Bellon H, Dubbeldam A, De Wever W, Dupont LJ, Van Raemdonck DE, Vanaudenaerde BM, Verleden GM, Benden C, Vos R.

J Heart Lung Transplant. 2016 Sep;35(9):1078-84. doi: 10.1016/j.healun.2016.03.022. Epub 2016 Apr 16.

PMID:
27212563
31.

Argon and xenon ventilation during prolonged ex vivo lung perfusion.

Martens A, Montoli M, Faggi G, Katz I, Pype J, Vanaudenaerde BM, Van Raemdonck DE, Neyrinck AP.

J Surg Res. 2016 Mar;201(1):44-52. doi: 10.1016/j.jss.2015.10.007. Epub 2015 Oct 12.

PMID:
26850183
32.

Morphometric Analysis of Explant Lungs in Cystic Fibrosis.

Boon M, Verleden SE, Bosch B, Lammertyn EJ, McDonough JE, Mai C, Verschakelen J, Kemner-van de Corput M, Tiddens HA, Proesmans M, Vermeulen FL, Verbeken EK, Cooper J, Van Raemdonck DE, Decramer M, Verleden GM, Hogg JC, Dupont LJ, Vanaudenaerde BM, De Boeck K.

Am J Respir Crit Care Med. 2016 Mar 1;193(5):516-26. doi: 10.1164/rccm.201507-1281OC.

PMID:
26551917
33.

Anastomotic airway complications after lung transplantation: risk factors, treatment modalities and outcome-a single-centre experience.

Yserbyt J, Dooms C, Vos R, Dupont LJ, Van Raemdonck DE, Verleden GM.

Eur J Cardiothorac Surg. 2016 Jan;49(1):e1-8. doi: 10.1093/ejcts/ezv363. Epub 2015 Oct 13.

PMID:
26464447
34.

Prophylactic Azithromycin Therapy After Lung Transplantation: Post hoc Analysis of a Randomized Controlled Trial.

Ruttens D, Verleden SE, Vandermeulen E, Bellon H, Vanaudenaerde BM, Somers J, Schoonis A, Schaevers V, Van Raemdonck DE, Neyrinck A, Dupont LJ, Yserbyt J, Verleden GM, Vos R.

Am J Transplant. 2016 Jan;16(1):254-61. doi: 10.1111/ajt.13417. Epub 2015 Aug 4.

35.

Combined or Serial Liver and Lung Transplantation for Epithelioid Hemangioendothelioma: A Case Series.

Desie N, Van Raemdonck DE, Ceulemans LJ, Nevens F, Verslype C, Vansteenbergen W, Pirenne J, Monbaliu D, Roskams T, Verbeken EK, Neyrinck AP, Dupont LJ, Yserbyt J, Verleden GM, Vos R.

Am J Transplant. 2015 Dec;15(12):3247-54. doi: 10.1111/ajt.13430. Epub 2015 Aug 19.

36.

BAL neutrophilia in azithromycin-treated lung transplant recipients: Clinical significance.

Vandermeulen E, Verleden SE, Ruttens D, Moelants E, Mortier A, Somers J, Bellon H, Piloni D, Dupont LJ, Van Raemdonck DE, Proost P, Schols D, Vos R, Verleden GM, Vanaudenaerde BM.

Transpl Immunol. 2015 Sep;33(1):37-44. doi: 10.1016/j.trim.2015.07.001. Epub 2015 Jul 11.

PMID:
26168736
37.

Linking clinical phenotypes of chronic lung allograft dysfunction to changes in lung structure.

Verleden SE, Vasilescu DM, McDonough JE, Ruttens D, Vos R, Vandermeulen E, Bellon H, Geenens R, Verbeken EK, Verschakelen J, Van Raemdonck DE, Wuyts WA, Sokolow Y, Knoop C, Cooper JD, Hogg JC, Verleden GM, Vanaudenaerde BM.

Eur Respir J. 2015 Nov;46(5):1430-9. doi: 10.1183/09031936.00010615. Epub 2015 Jun 25.

38.

Editorial Commentary: A New Set of Lungs or a New Pair of Glasses?

Van Raemdonck DE.

Semin Thorac Cardiovasc Surg. 2015 Spring;27(1):15-6. doi: 10.1053/j.semtcvs.2015.02.009. Epub 2015 Feb 26. No abstract available.

PMID:
26074104
39.

Interleukin-17 receptor polymorphism predisposes to primary graft dysfunction after lung transplantation.

Somers J, Ruttens D, Verleden SE, Vandermeulen E, Piloni D, Wauters E, Lambrechts D, Vos R, Verleden GM, Vanaudenaerde B, van Raemdonck DE.

J Heart Lung Transplant. 2015 Jul;34(7):941-9. doi: 10.1016/j.healun.2015.03.009. Epub 2015 Mar 26.

PMID:
25935436
40.

Role of genetics in lung transplant complications.

Ruttens D, Vandermeulen E, Verleden SE, Bellon H, Vos R, Van Raemdonck DE, Dupont LJ, Vanaudenaerde BM, Verleden GM.

Ann Med. 2015 Mar;47(2):106-15. doi: 10.3109/07853890.2015.1004359. Epub 2015 Mar 13. Review.

PMID:
25766881
41.

Restrictive chronic lung allograft dysfunction: Where are we now?

Verleden SE, Ruttens D, Vandermeulen E, Bellon H, Van Raemdonck DE, Dupont LJ, Vanaudenaerde BM, Verleden G, Vos R.

J Heart Lung Transplant. 2015 May;34(5):625-30. doi: 10.1016/j.healun.2014.11.007. Epub 2014 Nov 11.

PMID:
25577564
42.

Azithromycin and the treatment of lymphocytic airway inflammation after lung transplantation.

Vos R, Verleden SE, Ruttens D, Vandermeulen E, Bellon H, Neyrinck A, Van Raemdonck DE, Yserbyt J, Dupont LJ, Verbeken EK, Moelants E, Mortier A, Proost P, Schols D, Cox B, Verleden GM, Vanaudenaerde BM.

Am J Transplant. 2014 Dec;14(12):2736-48. doi: 10.1111/ajt.12942. Epub 2014 Nov 13.

43.

A decade of extended-criteria lung donors in a single center: was it justified?

Somers J, Ruttens D, Verleden SE, Cox B, Stanzi A, Vandermeulen E, Vos R, Vanaudenaerde BM, Verleden GM, Van Veer H, Coosemans W, Decaluwe H, Nafteux P, De Leyn P, Van Raemdonck DE.

Transpl Int. 2015 Feb;28(2):170-9. doi: 10.1111/tri.12470. Epub 2014 Oct 30.

44.

Are we near to an effective drug treatment for bronchiolitis obliterans?

Verleden GM, Vos R, Dupont L, Van Raemdonck DE, Vanaudenaerde BM, Verleden SE.

Expert Opin Pharmacother. 2014 Oct;15(15):2117-20. doi: 10.1517/14656566.2014.954549. Epub 2014 Aug 25.

PMID:
25154562
45.

Differential cytokine, chemokine and growth factor expression in phenotypes of chronic lung allograft dysfunction.

Verleden SE, Ruttens D, Vos R, Vandermeulen E, Moelants E, Mortier A, Van Raemdonck DE, Proost P, Schols D, Verleden GM, Vanaudenaerde BM.

Transplantation. 2015 Jan;99(1):86-93. doi: 10.1097/TP.0000000000000269.

PMID:
25050473
46.

Body mass index in lung transplant candidates: a contra-indication to transplant or not?

Ruttens D, Verleden SE, Vandermeulen E, Vos R, van Raemdonck DE, Vanaudenaerde BM, Verleden GM.

Transplant Proc. 2014 Jun;46(5):1506-10. doi: 10.1016/j.transproceed.2014.04.004.

PMID:
24935321
47.

Genetic variation in immunoglobulin G receptor affects survival after lung transplantation.

Ruttens D, Verleden SE, Goeminne PC, Vandermeulen E, Wauters E, Cox B, Vos R, Van Raemdonck DE, Lambrechts D, Vanaudenaerde BM, Verleden GM.

Am J Transplant. 2014 Jul;14(7):1672-7. doi: 10.1111/ajt.12745. Epub 2014 May 6.

48.

Mechanistic differences between phenotypes of chronic lung allograft dysfunction after lung transplantation.

Suwara MI, Vanaudenaerde BM, Verleden SE, Vos R, Green NJ, Ward C, Borthwick LA, Vandermeulen E, Lordan J, Van Raemdonck DE, Corris PA, Verleden GM, Fisher AJ.

Transpl Int. 2014 Aug;27(8):857-67. doi: 10.1111/tri.12341. Epub 2014 Jun 17.

49.

Genetic variation in caveolin-1 affects survival after lung transplantation.

Vandermeulen E, Ruttens D, Verleden SE, Vos R, Van Raemdonck DE, Kastelijn EA, Wauters E, Lambrechts D, Nawrot TS, Cox B, Verleden GM, Vanaudenaerde BM.

Transplantation. 2014 Aug 15;98(3):354-9. doi: 10.1097/TP.0000000000000058.

PMID:
24621537
50.

Functional and computed tomographic evolution and survival of restrictive allograft syndrome after lung transplantation.

Verleden SE, de Jong PA, Ruttens D, Vandermeulen E, van Raemdonck DE, Verschakelen J, Vanaudenaerde BM, Verleden GM, Vos R.

J Heart Lung Transplant. 2014 Mar;33(3):270-7. doi: 10.1016/j.healun.2013.12.011. Epub 2013 Dec 17.

PMID:
24461432

Supplemental Content

Loading ...
Support Center